Humanized Communications - Greater Salt Lake City Area since Jan 2012
Technology Analyst
IncSpot Productions, LLC - Utah Oct 2001 - May 2013
Owner/Consultant
Delta Health Systems - Salt Lake City, Utah Oct 2009 - Oct 2011
IT Analyst
P5 Health Plan Solutions Jan 2004 - Oct 2009
IT Director
P5 Health Plan Solutions Jun 1999 - Jan 2004
IT Analyst/Project Director
Education:
University of Phoenix 1989 - 1991
BSBA, Business Administration
University of Utah 1986 - 1989
Bachelor of Business Administration (BBA), Business Administration and Management, General
Brigham Young University - Idaho 1982 - 1985
AA, Political Science
SkyView High School 1979 - 1981
Skills:
SEO InBound Marketing Video Production EDI Microsoft Office Budgeting Social Media iSeries IBM iSeries Wordpress After Effects Social Business Design Web Development Web Design Business Analysis Flash Professional Network Administration System Administration Project Management Security Graphic Design Analysis Disaster Recovery Business Intelligence Management Project Planning Business Strategy Systems Analysis High Availability Google Analytics Networking Web Project Management IT Management Web Analytics E-commerce Business Continuity Team Leadership Cloud Computing Microsoft SQL Server Software Development DB2 Information Technology Integration Budgets Testing Databases Technical Support WordPress Outsourcing VPN
Eldon Scott Priestley - Yardley PA, US Daniel L. Cheney - Ringoes NJ, US Nicolas Ronald Wurtz - Pennington NJ, US Peter W. Glunz - Yardley PA, US
International Classification:
A61K 31/4725 C07D 245/00 A61P 7/02
US Classification:
514310, 540456, 540460
Abstract:
The present invention relates generally to novel macrocycles of Formula (I):or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R, R, R, R, R, R, R, R, R, and Rare as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.
Azacyclic Bisphosphonates As Anticholesterolemic Agents
John W. Ullrich - Philadelphia PA Raymond D. Youssefyeh - Princeton Junction NJ Daniel L. Cheney - Audubon PA Christopher J. Burns - Bryn Mawr PA
Assignee:
Rhone-Poulenc Rorer Pharmaceuticals Inc. - Collegeville PA
International Classification:
A61K 31675 A61K 3166
US Classification:
514 79
Abstract:
This invention relates to a method of lowering abnormally high serum cholesterol levels in the body without significantly reducing mevalonic metabolite synthesis and to novel pharmacological compositions containing as an active ingredient bisphosphonic acid and ester compounds containing a mono-, bi- or tricyclic ring linked with a bisphosphonate moiety through a basic amino alkylene group. This invention also provides novel bisphosphonate compounds and the processes for their preparation.
Substituted (Sulfinic Acid, Sulfonic Acid, Sulfonylamino Or Sulfinylamino) N-[(Aminoiminomethyl)Phenylalkyl]-Azaheterocyclylamide Compounds
William R. Ewing - King of Prussia PA Michael R. Becker - Norristown PA Henry W. Pauls - Collegeville PA Daniel L. Cheney - West Chester PA Jonathan S. Mason - Dagenham, GB Alfred P. Spada - Lansdale PA
Assignee:
Rhone-Poulenc Rorer Pharmaceuticals Inc. - Collegeville PA
International Classification:
C07D40102 A61K 3140 A61K 31435
US Classification:
514309
Abstract:
The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.